Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cynvenio Biosystems developed blood-based molecular diagnostic tests for early detection, monitoring, and treatment guidance of cancers. Its platforms enabled real-time analysis of circulating tumor cells and genetic mutations from a simple blood draw. The company’s ClearID® test targeted over fifty oncogenes relevant to breast cancer using next-generation sequencing. Its technologies were validated in pilot studies for lung nodule assessment and recurrent breast cancer detection. In May 2019, the company changed its name to LungLife AI.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cynvenio Biosystems.